



1H19 Results Presentation

22 February 2019

Myles Anceschi, CEO
Vinod Somani, CFO



DISCLAIMER

- This presentation has been prepared by BWX Limited ACN 163 488 631 (BWX) The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This presentation is provided to you on the basis that you are a “sophisticated investor” (in accordance with subsection 708(8) or (10) of the Corporations Act 2001 (Cth) (Corporations Act)) or a “professional investor” (in accordance with subsection 708(11) of the Corporations Act). The information contained in this presentation is for information purposes only.
- The information contained in this presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing this presentation, BWX has not considered the objectives, financial position or needs of any particular recipient. BWX strongly suggests that investors consult a financial advisor prior to making an investment decision. This presentation is strictly confidential and is intended for the exclusive benefit of the persons to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of BWX. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of BWX, its related bodies corporate, shareholders or respective directors, officers, employees, agents or advisors, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation.
- This presentation may include “forward looking statements”. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” “guidance” and other similar expressions. Indications of, and guidance on, future earning or dividends and financial position and performance are also forward looking statements. These forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BWX and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in those statements. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward looking statements and BWX assumes no obligation to update that information.
- This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities and neither this presentation nor anything contained in it forms the basis of any contract or commitment.
- This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities of BWX have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.
- This presentation may include certain financial measures that may be considered “non-GAAP financial measures” under Regulation G of the U.S. Securities Exchange Act of 1934, as amended, and are not recognised under AAS or International Financial Reporting Standards (IFRS). These measures include EBITDA, Adjusted EBITDA, net debt, pro forma net debt, and EBIT. Such non-GAAP and non-IFRS financial measures do not have a standardised meaning prescribed by AAS or IFRS. Therefore, the non-IFRS financial information is not a measure of financial performance, liquidity or value under the IFRS and may not be comparable to similarly titled measures presented by other entities, and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. The information is presented to assist in making appropriate comparisons with prior periods and to assess the operating performance of the business. BWX use these measures to assess the performance of its business and it considers that this non-IFRS information is important to assist in evaluating its performance. You are cautioned not to place undue reliance on any non-GAAP and non-IFRS financial measures included in this presentation. The information provided may be unaudited.

AGENDA

- 1H19 summary
- Financial summary
- Brand update
- Strategy scorecard & outlook
- Q&A

ersonal use only



1H19 SUMMARY

ersonal use only

KEY MESSAGES

- Revenue +1.4% to \$68.1m; reported EBITDA of \$7.2m; underlying¹ EBITDA of \$7.1m in-line with December 2018 trading update
- Sukin and acquired brand retail point of sales performance and market shares remain strong
- Significant improvement in Q2 operating performance including early stage benefits from transformation programs
- Cash flow in 1H19 impacted by inventories and prepayments that will benefit 2H19
- No interim dividend declared: dividend outlook to be reviewed at full-year results
- FY19 guidance update: Underlying EBITDA in the range of \$27m-\$29m (previously \$27-\$32m)


1. Underlying is a non-IFRS measure that excludes non-recurring items

1H19 DYNAMICS

CHALLENGES	1Q19	2Q19	OUTCOMES/STATUS
Failed MBO: Significant drain on resources when critical initiatives were in execution phase			Discussions with bid consortium concluded mid-Sept. 2018. Management now 100% focused on transformation
ERP Upgrade: return to normal operations impacted resulting in lost sales, higher costs			ERP fully operational in Australia: starting to deliver expected benefits. US roll-out postponed to Q1 FY '20
Warehouse relocations/consolidations: lost sales and higher costs during transition			Completed end 1Q19: Increased Nourished Life capacity by 4x. US facility consolidation delivers cost and leverage benefits
Delayed roll-out of multi-brand selling model: lost sales and retailer leverage			H2 traction: Sukin selling in 400+ US Natural doors, UK & Canada consolidation in H2
Temporary loss of sales momentum in US: Key personnel appointments delayed, volatile US retail sales in Q2			Early signs of improved US momentum: Key appointments and new resource capable of delivering target outcomes, stabilisation of US retail sales
Mineral Fusion rebranding: slowing down to speed up. Relaunch pushed back 3 months			Launched January 2019 with encouraging initial results
Soft export trading sales to China			Further refined go-to-market strategy: signed exclusive distribution agreement effective December 2018


GROUP QUARTERLY SUMMARY

Net revenue (AUD million)



- Net revenue +1.4% to \$68.1m
- 2Q net revenue +55% compared to Q1


Underlying EBITDA (AUD million)




- Strong turnaround in 2Q EBITDA
- 2Q transformation momentum carries into H2

BRAND QUARTERLY DETAIL

Sukin net revenue (AUD million)



Nourished Life net revenue (AUD million)




- Top line impact of ERP upgrade
- Soft export trading sales to China
- Revised domestic and international strategy commenced in H2 FY18

- Affected by warehouse relocation and ERP upgrade
- Momentum regained in Q2

BRAND QUARTERLY SUMMARY


Andalou Naturals net revenue (USD million)



	2Q18	1H18	1Q19	2Q19	1H19
Revenue (AUD)	8.2	8.2	10.0	13.1	23.1

- Momentum building each quarter as innovation rolls out and base line sales improve

Mineral Fusion net revenue (USD million)



	1Q18	2Q18	1H18	1Q19	2Q19	1H19
Revenue (AUD)	6.4	7.1	13.5	4.2	5.7	9.9

- H1 impacted by delay in rebranding and associated restriction on brand activity

**FINANCIAL
SUMMARY**

ersonal use only

PROFIT AND LOSS

AUD million	1H18	1H19	Change
Revenue	67.2	68.1	1.4%
Gross Profit	40.0	35.1	-12.3%
Gross Profit Margin	59.6%	51.5%	-8.1pp
EBITDA – Reported	12.1	7.2	-40.5%
EBITDA - Underlying ¹	17.5	7.1	-59.5%
Depreciation & Amortisation	-0.9	-1.4	43.0%
Interest Expense	-1.9	-2.8	45.5%
Tax – Reported	-3.8	-0.4	
Tax – Underlying ¹	-3.9	1.1	
NPAT - Reported	5.4	2.6	-51.8%
NPAT – Underlying ¹	10.8	4.0	-62.6%
Basic EPS - Reported	5.2	2.1	-3.1cps
Basic EPS – Underlying ¹	10.4	3.2	-7.2cps
Dividends per share	3.3	-	-3.3cps

1. Underlying is a non-IFRS measure that excludes non-recurring items. Refer Appendix for a reconciliation of reported to underlying

Net revenue:

64% of net revenue comprised of the three acquired businesses (1H18: 43%)

Gross Profit:

- Group gross profit margin impacted by an increased proportion of net revenue coming from the acquired businesses
- Sukin brand gross profit margin % in-line with 1H18

Operating expenses:

84% of increase in operating expenses (vs.1H18) is attributable to the acquired businesses (Andalou Naturals & Nourished Life) being in operation for full six-months during 1H19

Depreciation & Amortisation:

Higher D&A due to recognition of intangibles stemming from finalisation of Nourished life acquisition

Tax:

Lower tax expense impacted by Andalou Naturals deferred payment

NON-RECURRING ITEMS

	1H18		1H19	
	Pre-tax	Post-Tax	Pre-tax	Post-Tax
Deferred consideration reversal	4.6	3.0	5.4	3.8
Costs relating to MBO proposal	-	-	-4.6	-4.5
Restructuring costs	-4.8	-3.9	-	-
Acquisition costs	-5.2	-4.4	-0.8	-0.8
Total	-5.5	-5.4	0.1	-1.4


BALANCE SHEET

AUD million	1H18	1H19	Change
Assets			
Cash	19.9	5.7	-71.6%
Trade and other receivables	31.2	30.4	-2.4%
Inventories	27.9	34.9	25.2%
Prepayments	1.8	6.1	236.8%
Plant and equipment	3.5	3.9	11.3%
Intangible assets and goodwill	274.3	284.5	3.7%
Deferred tax assets	3.2	6.1	92.1%
Total Assets	361.8	371.7	2.7%
Liabilities			
Trade and other payables	16.2	22.9	41.6%
Financial liabilities	72.8	69.7	-4.3%
Current tax liabilities	1.4	0.4	-69.3%
Employee benefits	1.4	1.2	-14.9%
Total liabilities	91.8	94.3	2.6%
Net assets	270.0	277.4	2.8%

- Cash impacted by lower EBITDA, working capital and deferred payment in relation to Andalou Naturals acquisition
- Lower financial liabilities due to a \$10.6m reduction in deferred consideration / payments on acquisitions, offset by movement in working capital banking facility
- All bank covenants obligations compliant as at 31 December 2018
- No adjustment to the carrying value of assets following December 2018 external review

	1H19
Debt	57.1
Deferred consideration	12.6
Total debt	69.7

WORKING CAPITAL



- Plans in place for inventories balance to reduce by 30 June 2019
- This, together with the unwind of prepayments, will provide a cash flow benefit in the second half

* Movement comprises Trade and other payables (+\$6.7m) and employee benefits (-\$0.2m)

CASH FLOW RECONCILIATION

AUD million	1H19
EBITDA (underlying)	7.1
Working Capital movements	-4.0
Transaction costs	-2.1
Interest expense	-1.9
Tax	-2.5
Other	-3.9
Operating Cash Flow	-7.3

AUD million	1H19
Capital Expenditure	-2.6

- EBITDA to Operating Cash Flow largely impacted by working capital movements
- Capital expenditure expected to be 1-2% of net revenue this financial year

	1H19
Working capital adjustment for transaction costs	-3.3
FX/other	-0.6
Total	-3.9


BRAND UPDATE

ersonal use only


SUKIN (34% OF GROUP SALES)

IRI Scan Data – Quarterly Units (000s) Share

Australia Pharmacy - Total Sukin



#1 skincare brand in Australian pharmacy (% market share)¹



- Marketing execution & brand activations effective
 - “Nothing but Special” Media campaign driving incremental growth
 - Digital re-launch and social media programs improving engagement
- Brand innovation supporting growth via entry into new segments
- Domestic availability-improvement strategy delivering results
- Refined international model improving sustainability of revenues


Outlook:

- Range expansion with existing and new trade partners
- Domestic performance strengthening via improved distribution
- Brand innovation will support growth in new opportunity segments
- International revenue growth from existing and new markets

¹ Universe excludes therapeutic skincare. IRI Market Edge Data – Australian Pharmacy Skin Care - Units Share – MAT to 20/01/19

NOURISHED LIFE (15% OF GROUP SALES)

Website Daily Order Average



Loyalty Club Membership Trend



- Platform upgrade work complete - user experience issues resolved
- Domestic growth rates remain strong
- B2C Consumer behavior intelligence leverage improving
- Improved systems with established team driving greater insights


Outlook:

- Strengthened platform to drive operating leverage
- Platform launch in 2 new international markets in H2
- Domestic organic growth robust with opportunity to improve
- Broader group procurement plan to support margin expansion
- APAC Model learnings create functional model for regional expansion


ANDALOU NATURALS (34% OF GROUP SALES)

SPINS and Nielsen Scan Data Q1, Q2, Q3, Q4¹ Sales (000s) Share

Total Share Andalou Facial Skin Care



#1 cosmetics brand in US natural channel (% market share)¹



- North American consumer sales strong, market shares growing
- Marketing execution focused on brand core and US channel opportunity
- Recent innovation & strong pipeline supporting brand share growth
- International integration with Sukin activities progressing




Outlook:

- Innovation and channel expansion to support growth
- International integration and registrations open new markets
- Internal manufacturing trial in H2 will quantify margin improvement opportunity
- Operating leverage from combined Andalou / MF / Sukin platform
- Broader group procurement plan to support margin expansion

¹: Based on SPINS 12 week data for period ending 30/12/18 and Nielsen Whole Foods data for period ending 29/12/18

MINERAL FUSION (15% OF GROUP SALES)

**#1 facial skincare
brand in US natural
channel
(% market share)¹**



- 2018 saw a planned re-brand to broaden consumer and channel appeal
- Significant work on the re-brand was delayed by 3 months resulting in:
 - Lost Q1 promotional intensity during the planned change period
 - Revised launch timing requiring sales activity restriction in Q2 in advance of packaging change-out in 1000+ doors.
- Despite this brand pause, market shares remain strong
- Upgraded livery now facilitating fresh discussions with retail partners
- Re-packaging supports new brand positioning and natural messaging

Outlook:

- Encouraging initial results from new branding launch in January 2019
- Improved brand platform to grow baseline and channel expansion
- Broader group procurement plan to support margin expansion 20
- Priceline test in H2 opportunity to refine international expansion model

¹: Based on SPINS 12 week data for period ending 30/12/18 and Nielsen Whole Foods data for period ending 29/12/18

PERSONAL USE ONLY

STRATEGY SCORECARD & OUTLOOK

STRATEGIC OBJECTIVES SCORECARD

H2 2019

FY 2020+

Objective	H2 2019	Progress	FY 2020+	Progress
1 Strengthen base revenues: 4 x core beauty and personal care brands and an e-commerce platform	<ul style="list-style-type: none"> Domestic brand market shares Distribution growth (core / innovation) Platform and Brand improvements 	●	<ul style="list-style-type: none"> Domestic brand market shares Distribution growth (core / innovation) Platform and Brand improvements 	●
2 Pursue meaningful geographic expansion: focused expansion in attractive and scalable markets	<ul style="list-style-type: none"> Sukin → US entry, doors build Andalou / MF → APAC International consolidation, model upgrade 	●	<ul style="list-style-type: none"> Sukin → 2 x major market launches Andalou / MF → EU expansion Nourished Life new geographies 	●
3 Accelerate channel expansion: grow market share in existing channels and expand in new opportunity channels	<ul style="list-style-type: none"> Sukin – Continue channel expansion Mineral Fusion – US Drug and Grocery Andalou – US Drug and Grocery 	●	<ul style="list-style-type: none"> Sukin – EU / US channel expansion Mineral Fusion – US / EU Drug and Grocery Andalou – US / EU Drug and Grocery 	●
4 Grow e-commerce presence: capitalise on BWX Digital capabilities to drive growth across all brands in B2C sales	<ul style="list-style-type: none"> Nourished Life – 2 x new test markets Sukin – Upgraded Web Platform leverage Andalou / MF – Upgraded Web Platform 	●	<ul style="list-style-type: none"> Nourished Life – 2 x new international mkts Sukin – Platform data leverage Andalou / MF – Platform data leverage 	●
5 Innovation to underpin growth: launch new initiatives in attractive segments that drive brand penetration and regime expansion	<ul style="list-style-type: none"> Nourished Life – Life Basics line extensions Sukin – 2 x expanded segment offers Andalou / MF – Recent launch distribution 	●	<ul style="list-style-type: none"> Nourished Life – Life Basics line extensions Sukin – 2 x new categories Andalou – 1 x major segment expansion 	●
6 Business optimisation: invest in manufacturing capabilities and drive operating synergies to improve capital returns	<ul style="list-style-type: none"> Strategic Procurement engagement Andalou in-house manufacturing trial Q4 NWC and Cash Flow programs H2 	●	<ul style="list-style-type: none"> Strategic Procurement Annual (Target TBC) Andalou in-house production expansion Production efficiency program (Target TBC) 	●

● Completed
 ● On track
 ● Behind schedule

OUTLOOK

- FY19 Guidance update: underlying EBITDA in the range of \$27m-\$29m (previously \$27-\$32m)
- Point of sales data highlights ongoing strength in our brands and provides confidence in traction with consumers across our portfolio
- Expect to see further growth in offshore markets as international re-set and consolidation progresses
- Improved conversion in earnings to cash in 2H 2019
- Capital expenditure within 1-2% of net revenues in FY19

ersonal use only

Thank you.

APPENDIX

- Reported to underlying reconciliation
- Group cash flow statement
- 1H19 underlying EBITDA by month
- Strategic channel expansion

ersonal use only




REPORTED TO UNDERLYING RECONCILIATION

AUD millions	1H18			1H19		
	Reported	Non-recurring	Underlying	Reported	Non-recurring	Underlying
Revenue	67.2		67.2	68.1		68.1
Gross Profit	40.0		40.0	35.1		35.1
Gross Profit Margin	59.6%		59.6%	51.5%		51.5%
EBITDA	12.1	5.5	17.5	7.2	-0.1	7.1
EBITDA Margin	17.9%		26.1%	10.4%		10.4%
Depreciation & Amortisation	-0.9		-0.9	-1.4		-1.4
EBIT	11.1	5.5	16.6	5.8	-0.1	5.7
Interest Expense	-1.9		-1.9	-2.8		-2.8
Tax	-3.8	-0.1	-3.9	-0.4	1.5	1.1
NPAT	5.4	5.4	10.8	2.6	1.4	4.0

GROUP CASH FLOW STATEMENT

AUD million	1H18	1H19
Cash flows from operations		
Receipts from customers	72.5	72.0
Payments to suppliers and employees	(54.6)	(73.1)
Payments for transaction costs	(7.5)	(2.1)
Income taxes paid	(4.9)	(2.5)
Other income received	0.02	0.3
Interest paid	(1.9)	(1.9)
Net cash from operating activities	3.7	(7.3)
Cash flow from investing activities		
Acquisition of plant and equipment	(0.4)	(1.2)
Acquisition of intangible assets	-	(1.4)
Net cash outflow on acquisition of business	(98.1)	(5.2)
Net cash flows used in investing activities	(98.5)	(7.9)
Cash flows from financing activities		
Proceeds from issue of share capital	128.2	0.9
Transaction costs for issue of shares	(4.5)	-
Dividends paid	(3.8)	(5.1)
Proceeds / (repayments) from borrowings	(9.4)	4.7
Net cash used in financing activities	110.6	0.5
Net (decrease) / increase in cash and cash equivalents	15.8	(14.6)
Effect of exchange rate changes on cash held	0.1	0.4
Cash and cash equivalents at beginning of period	11.0	19.9
Cash and cash equivalents at end of period	26.9	5.7

1H19 UNDERLYING EBITDA
BY MONTH (\$Am)



ersonal use only

STRATEGIC CHANNEL EXPANSION

Strategic focus



	sukin					ANDALOU					MINERAL FUSION™					Nourished Life					BWXLtd					
	Mass & Grocery	Drug / Pharmacy	Natural	Other	e-commerce	Mass & Grocery	Drug / Pharmacy	Natural	Other	e-commerce	Mass & Grocery	Drug / Pharmacy	Natural	Other	e-commerce	Mass & Grocery	Drug / Pharmacy	Natural	Other	e-commerce	Mass & Grocery	Drug / Pharmacy	Natural	Other	e-commerce	
Australia	Dark Green	Dark Green	Dark Green	Light Green	Dark Green	Light Gray	Light Gray (Strategic focus)	Light Gray	Light Gray	Light Gray	Light Gray	Dark Gray (Strategic focus)	Dark Gray	Dark Gray	Dark Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Orange	Orange	Orange	Light Orange	Orange
U.S.	Light Green (Strategic focus)	Light Green (Strategic focus)	Light Green (Strategic focus)	Light Green (Strategic focus)	Light Green (Strategic focus)	Dark Gray	Dark Gray	Dark Gray	Dark Gray	Dark Gray	Dark Gray	Dark Gray	Dark Gray	Dark Gray	Dark Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Orange	Orange	Orange	Orange	Orange
Canada	Dark Green	Dark Green	Dark Green	Light Green	Light Green	Light Gray	Dark Gray	Light Gray	Light Gray	Light Gray	Light Gray	Dark Gray	Light Green	Light Gray	Light Green	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Orange	Orange	Orange	Light Orange	Orange
Europe	Light Green	Dark Green	Dark Green	Light Green	Dark Green	Light Gray	Light Gray (Strategic focus)	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray (Strategic focus)	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Orange	Orange	Orange	Light Orange	Orange
Asia	Light Green (Strategic focus)	Dark Green	Light Green	Light Green	Dark Green	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray	Light Gray (Strategic focus)	Light Orange	Orange	Light Orange	Light Orange	Orange

Personal use only